Zura Bio Limited

Healthcare · Biotechnology · United States

Last price 4.04 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 389.15M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and C...